• RT001 – Retrotope

    Posted by Christina Cordaro on September 23, 2020 at 5:26 pm

    The Friedreich’s Ataxia Research Alliance is getting closer to full enrollment in October:

    Retrotope is seeking 25 additional participants, ages 12-50, in a clinical trial for the drug RT001, which is designed to protect against lipid peroxidation, the process that is believed to cause disability in many neurodegenerative diseases, including Friedreich’s ataxia.

    This study will involve five visits to a research clinic over a 12-month period. Sites are open at Children’s Hospital of Philadelphia, Long Beach CNS, UCLA, University of Iowa, University of South Florida and University of Florida-Gainesville. Click the link for eligibility criteria and study information: bit.ly/37sith1

    Christina Cordaro replied 3 years, 8 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.